< Back to the team

S.LOZE

Board member

PharmD

Stéphane Loze is a highly experienced healthcare professional with over 20 years of experience in the field.

He currently serves as an Administrator for Angels Santé and a Board Member for the French Society of Predictive & Personalized Medicine (SFMPP).

Prior to this, he was the Head of Strategy & Therapeutic units at Roche France.

Stéphane  is committed to improving patient outcomes through healthcare innovation.

Linkedin-in

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

More about Haptenization & STC immunogenicity
Back to the page

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)
Back to the page

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with a broad & higher quality range of tumor antigens

More about STC Antigenicity
Back to the page